TGF-beta inhibitor, preparation thereof and application of TGF-beta inhibitor in preparation of antitumor drugs
By designing TGF-β inhibitor compounds with specific structural formula 1 and preparing them by coupling reaction methods, the existing TGF-β inhibitors have been solved, and effective inhibition of the TGF-β signaling pathway is achieved and improve anti-tumor effects.
Patent Information
- Application Number
- CN202411071565.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-19
AI Technical Summary
The selectivity of existing TGF-β inhibitors is low, resulting in obvious side effects and is not effective in treating tumors, making it difficult to effectively inhibit the progress of TGF-β signaling pathway-related diseases.
A brand new TGF-β inhibitor compound has been developed, which has a specific structural formula 1. By optimizing the design of R groups, it can work synergistically to improve TGF-β inhibitory activity and be used to prepare anti-tumor drugs. The compound is prepared by coupling reaction method, using specific precursor materials and catalysts to form drugs with high selectivity and low side effects.
Effective inhibition of TGF-β signaling pathway was achieved, significantly improved anti-tumor effect, reduced side effects of the drug, and provided higher selectivity and better therapeutic effects.
Smart Images

Figure CN118978520A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to the field of a class of TGF-β inhibitors. Background Art
[0002] Transforming growth factor-β (TGF-β) is an important multifunctional cytokine that participates in many cellular processes, including cell proliferation, differentiation, self-renewal, and apoptosis. It is divided into six subtypes (TGFβ1 to 6) based on its homology. TGF-β1 is a prototype cytokine of the TGF-β family and transmits signals through two highly conserved single transmembrane serine / threonine kinase receptors, namely TGF-β1 receptor (also known as ALK5) and TGF-β2 receptor. In the classic TGF-β signaling pathway, TGF-β1 dimers bind to TGF-β2 receptors and induce phosphorylation of the GS domain of type 1 receptors. TGF-β1 receptors are then phosphorylated at the carbon terminus, recruiting and phosphorylating Smad2 or Smad3. Phosphorylated Smad proteins form heterologous complexes with Smad 4 and translocate to the nucleus to regulate the expression of specific genes, thereby participating in the processes of angiogenesis, epithelial-mesenchymal transition, and extracellular matrix remodeling. In addition, TGF-β balances the production and effector functions of many immune cell types in the adaptive and innate immune systems (E. Batlle, et al., Immunity. 2019; 50: 924-940.). Recent studies have shown that TGF-β plays a central role in tumor immune evasion and adverse reactions to cancer immunotherapy. The combination of TGF-β signaling blockade and checkpoint therapy can sensitize primary tumors and metastases to anti-PD-1 / L1 therapy, thereby enhancing immune responses (S. Mariathasan, et al., Nature, 2018, 554: 544-548.).
[0003] TGF-β1 is the most common and important subtype of the TGF-β superfamily, and is also the strongest known inducing factor of liver fibrosis (Yamazaki, et al., Digestive Disease, 2011, 29: 284-288). Many studies have shown that TGF-β1 and TGF-β1 receptors are highly expressed in diseases such as liver fibrosis and hepatocellular carcinoma. TGF-β1 regulates the expression of a series of genes related to fibrosis and tumor progression through the action domain TGF-βR1 (HJBaek, et al., Hepatology. 2008; 48: 1128-37.). Therefore, inhibiting the TGF-β signaling pathway is considered a feasible method to alleviate the progression of these diseases.
[0004] Drug development targeting the TGF-β signaling pathway has been carried out for many years. The TGF-βR1 inhibitors developed earlier usually show certain side effects such as cardiotoxicity in animal models due to their low selectivity (EF Wagner, et al., Nature Reviews Cancer. 2009; 9: 537-49). Inhibitors that have entered the clinical stage, such as Galunisertib and LY3200882, have limitations such as poor monotherapy effects. Therefore, those skilled in the art are still eager to obtain TGF-β1 inhibitors with higher selectivity and lower side effects for the treatment of diseases related to the TGF-β signaling pathway. Summary of the invention
[0005] In view of the problem that the activity of existing TGF-β inhibitors is not ideal, the first purpose of the present invention is to provide a TGF-β inhibitor with a completely new structure, aiming to improve its TGF-β inhibitory activity and anti-tumor activity.
[0006] The second object of the present invention is to provide a method for preparing a TGF-β inhibitor and its use in preparing a drug for inhibiting TGF-β.
[0007] The third object of the present invention is to provide an anti-tumor drug comprising the TGF-β inhibitor.
[0008] A TGF-β inhibitor, which is a compound having a structure of Formula 1 and at least one of its pharmaceutically acceptable salts, derivatives, cocrystals, crystals, and solvates;
[0009]
[0010] The R is a N-containing monocyclic ring with a substituent; wherein the N-containing monocyclic ring is a four-membered to six-membered saturated N-containing heterocyclic ring containing 1 to 2 N atoms, or a five-membered to six-membered N-containing aromatic heterocyclic ring containing 1 to 2 N atoms; the substituent includes at least one of halogen, -CN, amino, substituted amino, and alkyl (such as C1 to C4 alkyl).
[0011] The present invention provides a novel compound of the structure of Formula 1, and the compound can unexpectedly achieve synergy based on its structure and the combined control of the R group, can improve TGF-β inhibitory activity, and can achieve a good anti-tumor effect.
[0012] In the present invention, Ar can be a benzene ring or a five-membered aromatic heterocyclic ring, and the five-membered aromatic heterocyclic ring is, for example, a thiophene ring, a pyran ring, and the like.
[0013] In the formula 1, the structure has formula a and / or formula b:
[0014]
[0015] In the above a, R is a group of the following structure:
[0016]
[0017] The R1 is F or -CN; R2 is F, -CN, or C1-C4 alkyl;
[0018] Preferably, the R1 and R2 are located on the same or different carbons;
[0019] The R3 is an alkyl group or an amino-substituted alkyl group (for example, a C1-C4 alkyl group substituted with at least one of tertiary alkyl amino groups, secondary alkyl amino groups and primary alkyl amino groups).
[0020] Preferably, in the formula b, R is an amino group with a substituent; wherein the substituent includes an alkyl group, a cycloalkyl group, a nitrogen-containing heterocycle or a substituted alkyl group; the substituted alkyl group is an alkyl group with at least one of a hydroxyl group and a trifluoromethyl group.
[0021] In the present invention, the formula 1 comprises at least one of the following structures;
[0022]
[0023]
[0024]
[0025] The present invention also provides a method for preparing the TGF-β inhibitor, which is obtained by coupling the compound of formula 2 with a precursor raw material for forming an R residue;
[0026]
[0027] Said X is halogen.
[0028] In the preparation method of the present invention, the precursor raw material is RH, which is coupled with formula 2, a base, a palladium catalyst, and a reaction aid to obtain the TGF-β inhibitor;
[0029] Preferably, the auxiliary agent is 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene;
[0030] Preferably, the molar ratio of RH to Formula 2, base, palladium catalyst and reaction aid is 1.2-1.5:1:0.05-0.1:0.1-0.2.
[0031] The RH is, for example, At least one of .
[0032] Preferably, the coupling solvent is at least one of 1,4-dioxane, N,N-dimethylformamide, and tetrahydrofuran;
[0033] Preferably, the coupling reaction temperature is 90-110°C.
[0034] In another preparation method of the present invention, the precursor material is R-(BOR4)2, which is subjected to Suzuki coupling with Formula 2 to obtain the TGF-β inhibitor;
[0035] The R4 is independently H or a C1-C4 alkyl group.
[0036] R-(BOR4)2 can be, for example,
[0037] Preferably, the palladium catalyst is tetrakis(triphenylphosphine)palladium;
[0038] Preferably, the molar ratio of R-(BOR4)2 to formula 2, base and palladium catalyst is 1.2-1.5:1:0.05-0.1.
[0039] Preferably, the coupling solvent is at least one of 1,4-dioxane, N,N-dimethylformamide, and tetrahydrofuran;
[0040] Preferably, the coupling reaction temperature is 80-100°C.
[0041] The present invention also provides an application of the TGF-β inhibitor in preparing a drug for inhibiting TGF-β expression.
[0042] In the application of the present invention, the TGF-β specifically refers to TGF-β1 (TGF-βR1);
[0043] The application of the present invention is to use it for preparing anti-tumor drugs.
[0044] The present invention also provides an anti-tumor drug, which comprises a pharmaceutically effective amount of a TGF-β inhibitor.
[0045] The anti-tumor drug of the present invention further comprises a pharmaceutically acceptable excipient;
[0046] In the present invention, the auxiliary materials include, for example, excipients, disintegrants, flavoring agents, pigments, sustained-release agents, lubricants and other auxiliary materials known in the industry.
[0047] In the present invention, the drug has a pharmaceutically acceptable dosage form, such as oral preparations, injection preparations, transdermal absorption preparations, etc.
[0048] Beneficial Effects
[0049] The present invention provides a novel compound of the structure of Formula 1, and the compound can unexpectedly achieve synergy based on its structure and the combined control of the R group, can improve TGF-β inhibitory activity, and can achieve a good anti-tumor effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1 is the hydrogen spectrum of formula 1-A;
[0051] Figure 2 is the carbon spectrum of formula 1-A;
[0052] Figure 3 is the hydrogen spectrum of formula 1-B;
[0053] Figure 4 is the carbon spectrum of formula 1-B;
[0054] Figure 5 is the hydrogen spectrum of formula 1-C;
[0055] Figure 6 is the carbon spectrum of formula 1-C;
[0056] Figure 7 is the hydrogen spectrum of formula 1-D;
[0057] Figure 8 is the carbon spectrum of formula 1-D;
[0058] Fig. 9 In vivo H22 xenograft tumor model study of Example 4 and Galunisertib
[0059] Fig.10 Tumor size of in vivo H22 xenograft tumor model of Example 4 and Galunisertib DETAILED DESCRIPTION
[0060] The embodiments of the present invention will be described in detail below with reference to examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be construed as limiting the scope of the present invention.
[0061] Unless otherwise specified, the experiments and methods described in the examples are basically carried out according to conventional methods well known in the art and described in various references. If specific conditions are not specified in the examples, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially. It is known to those skilled in the art that the examples describe the present invention by way of example and are not intended to limit the scope of the protection claimed in the present invention. All public cases and other references mentioned herein are incorporated herein by reference in their entirety.
[0062] Synthesis and structural characterization of compounds
[0063] Example 1 Formula 1-A
[0064]
[0065] Step 1: Synthesis of Intermediate 1
[0066]
[0067] 7-Bromo-4-hydroxyquinoline (1 g, 4.5 mmol) was dissolved in N, N-dimethylformamide (15 mL), 2-bromo-1-(tetrahydro-2H-pyran-4-yl)ethanone (1.2 g, 5.6 mmol) and potassium carbonate (0.8 g, 5.6 mmol) were added, and the mixture was stirred at 60°C for 4 hours. After the reaction was completed by TLC, the mixture was cooled to room temperature, dissolved in water (100 mL), extracted three times with ethyl acetate (100 mL), the organic phase was washed with a saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and the crude product was separated by column chromatography (DCM / MeOH=20 / 1) to obtain 0.78 g of a white solid (Intermediate 1), with a yield of 50%.
[0068] Step 2-Synthesis of Intermediate 2
[0069]
[0070] Take intermediate 1 (0.79g, 2.2mmol) and N,N-dimethylformamide dimethyl acetal (2mL) in a pear-shaped bottle, heat and stir at 100℃ for 2 hours. After the reaction is completed, cool to room temperature, concentrate under reduced pressure, dissolve the residue in ethyl acetate (30mL), and wash three times with saturated sodium chloride solution (50mL). Dry the organic phase with anhydrous sodium sulfate, concentrate under reduced pressure, transfer to a reaction bottle, add acetic acid (10mL) and hydrazine hydrate (0.5mL), stir at room temperature and react overnight. After the reaction is completed, pour the reaction solution into ice water, extract with ethyl acetate (100mL), concentrate under reduced pressure, and purify by column chromatography (DCM / MeOH=20 / 1) to obtain 0.41g of white solid (intermediate 2), with a yield of 49%.
[0071] Step 3 Intermediate 3
[0072]
[0073] Add intermediate 2 (0.41 g, 1.1 mmol), copper acetate (0.21 g, 1.2 mmol), 2,2'-bipyridine (0.17 g, 1.2 mmol), cyclopropylboronic acid (0.22 g, 2.1 mmol) and sodium carbonate (0.23 g, 2.1 mmol) to the reaction bottle, add 1,2-dichloroethane (5 mL), and heat the reaction system at 80 ° C under an oxygen atmosphere for 2 hours. After the reaction is completed by TLC detection, cool to room temperature, add water (100 mL) to dissolve, extract three times with ethyl acetate (100 mL), wash the organic phase with saturated sodium chloride aqueous solution, add anhydrous sodium sulfate to dry, and separate the crude product by column chromatography (DCM / MeOH=20 / 1) to obtain 0.26 g of white solid (intermediate 3), with a yield of 78%. 1 H NMR (400MHz, DMSO-d6) δ8.73(d,J=5.2Hz,1H),8.25(s,1H),8.23(s,1H),7.98(s,1H),7.80(d,J=8.8Hz,1H),6.83(d,J=5. 2Hz,1H),3.84–3.65(m,3H),3.32–3.18(m,2H),2.81–2.68(m,2H),1.72–1.58(m,4H),1.06(s,2H),0.95(d,J=7.2Hz,2H). 13 C NMR (101MHz, DMSO-d6) δ161.97,153.53,150.17,145.85,133.62,131.19,130. 10,124.18,123.93,123.17,119.42,103.98,67.26,33.77,32.94,31.72,6.65.
[0074] Step 4 Synthesis of Formula 1-A
[0075]
[0076] Intermediate 3 (0.15 g, 0.36 mmol), 3,3-difluorotrimethyleneimine hydrochloride (precursor, 0.06 g, 0.43 mmol), palladium acetate (0.01 g, 0.04 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthene (0.05 g, 0.08 mmol), cesium carbonate (1.0 g, 1.1 mmol) were added to a three-necked flask, 1,4-dioxane (5 mL) was added to dissolve, and stirred at 100 ° C for 4 hours under an argon atmosphere. Cool to room temperature, add water (100 mL) to dissolve, extract three times with ethyl acetate (100 mL), wash the organic phase with saturated sodium chloride aqueous solution, add anhydrous sodium sulfate to dry, and separate the crude product by column chromatography (DCM / MeOH=10 / 1) to obtain 0.06 g of a white solid (Formula 1-A), with a yield of 39%. 1 H NMR (400MHz, CDCl3) δ8.55 (dd, J=5.2, 2.0Hz, 1H), 8.19 (dd, J=8.8, 2.0Hz, 1H), 7.36
[0077] (s,1H),6.97(s,1H),6.84(dt,J=9.2,2.0Hz,1H),6.45(dd,J=5.2,2.0Hz,1H),4.36(t,J=12.0Hz,4H),3.92–3.88(m,2H),3.56(tt,J=7.2 ,3.6Hz,1H),3.34(td,J=11.6,2.8Hz,2H),2.83–2.75(m,1H),1.91–1.81(m,2H),1.75–1.67(m,2H),1.13–1.09(m,2H),1.04–1.00(m,2H). 13 CNMR(101MHz,DMSO)δ161.86,152.45,151.24,150.97,145.91,133.94,123.08,122.72,117.10(t,J =273.9Hz),115.84,113.69,107.69,100.87,67.29,63.33(t,J=25.6Hz),33.71,33.05,31.69,6.61. 19 FNMR (376MHz, DMSO) δ-98.72.
[0078] Example 2 Formula 1-B
[0079]
[0080] The preparation method is the same as that in Example 1, except that in step 4, the precursor material is replaced with an equimolar amount of 3-methyl-3-cyanoazetidine hydrochloride to prepare a compound of formula 1-B.1 H NMR (400MHz, CDCl3) δ8.52(d,J=5.2Hz,1H),8.15(d,J=8.8Hz,1H),7.34(s,1H),6.88(d,J=2.0Hz,1H),6.76
[0081] (dd,J=8.8,2.4Hz,1H),6.42(d,J=5.2Hz,1H),4.33(d,J=7.2Hz,2H),3.92(d,J=7.6Hz,2H),3.87(ddd,J=11.6,4.4,2.0Hz,2H),3.53(tt,J=7 .2,3.6Hz,1H),3.31(td,J=11.6,2.4Hz,2H),2.80–2.73(m,2H),1.89– 1.78(m,2H),1.75–1.68(m,5H),1.10–1.06(m,2H),1.00–0.96(m,2H). 13 CNMR (101MHz, CDCl3) δ162.32,151.88,151.21,150.91,146.78,134.27,122.91,122.31,121 .99,114.08,113.87,106.65,100.45,67.86,61.64,33.32,33.24,31.42,27.25,23.52,6.51.
[0082] Example 3 Formula 1-C
[0083]
[0084] The preparation method is the same as that in Example 1, except that in step 4, the precursor material is replaced with an equimolar amount of 3,3-difluoropyrrolidine hydrochloric acid to obtain the title compound. 1 H NMR (400MHz, CDCl3) δ8.52 (d, J = 5.2Hz, 1H),
[0085] 8.16(d,J=9.2Hz,1H),7.35(s,1H),7.00(d,J=2.4Hz,1H),6.94(dd,J=9.2,2.4Hz,1H),6.40(d,J= 5.2Hz,1H),3.89(ddd,J=11.6,4.4,2.4Hz,2H),3.79(t,J=13.2Hz,2H),3.66(t,J=7.2Hz,2H),3.5 5(tt,J=7.2,3.6Hz,1H),3.33(td,J=11.6,2.0Hz,2H),2.79(tt,J=11.6,4.0Hz,1H),2.57–2.47(m ,2H),1.91–1.81(m,2H),1.73(ddd,J=12.8,4.0,2.0Hz,2H),1.11–1.08(m,2H),1.06–0.93(m,2H). 13 CNMR(101MHz, CDCl3)δ162.29,151.79,151.30,148.18,146.83,134.39,127.85(t,J=248.4Hz),122.82,121.95,114. 75,113.21,106.69,99.99,67.88,55.24(t,J=31.6Hz),45.59,34.19(t,J=24.0Hz),33.34,33.23,31.48,31.43,6.51. 19 FNMR (376MHz,CDCl3)δ-99.44.
[0086] Example 4 Formula 1-D
[0087]
[0088] Compared with Example 1, the only difference is that in step 4, intermediate 3 and 1-[2-(dimethylamino)ethyl]-1H-pyrazole-4-boronic acid (0.13 g, 0.72 mmol), tetrakis(triphenylphosphine)palladium (0.05 g, 0.04 mmol), potassium phosphate (0.23 g, 1.1 mmol) are added to a three-necked flask, 1,4-dioxane (5 mL) is added to dissolve, and the reaction is stirred at 90° C. under an argon atmosphere overnight. Cool to room temperature, add water (100 mL) to dissolve, extract three times with ethyl acetate (100 mL), wash the organic phase with a saturated sodium chloride aqueous solution, add anhydrous sodium sulfate to dry, and separate the crude product by column chromatography (DCM / MeOH=10 / 1) to obtain 0.05 g of a white solid with a yield of 30%. 1 HNMR
[0089] (400MHz, CDCl3) δ8.65 (d, J=5.2Hz, 1H),
[0090] 8.28(d,J=8.4Hz,1H),8.16(s,1H),7.92(d,J=11.6Hz,2H),7.76–7.66(m,1H),7.38(s,1H ),6.60(d,J=5.2Hz,1H),4.29(t,J=6.4Hz,2H),3.95–3.88(m,2H),3.58(tt,J=7.2,3.6Hz, 1H),3.35(t,J=11.6Hz,2H),2.84–2.81(m,1H),2.30(s,6H),2.24(d,J=7.2Hz,2H),1.88( dt,J=12.4,4.4Hz,2H),1.76(d,J=13.2Hz,2H),1.15–1.11(m,2H),1.02(q,J=10.8Hz,2H). 13 CNMR(101MHz, CDCl3)δ162.21,151.54,150.22,146.82,137.11,134.76,134.35,127.28,124.65,124 .09,122.19,122.09,121.85,119.17,102.21,67.86,59.04,50.60,45.55,33.33,31.46,24.77,6.50.
[0091] Example 5
[0092]
[0093] Step 1 Synthesis of intermediate 4
[0094]
[0095] Compared with Example 1, the only difference is that in step 1, 7-bromo-4-hydroxyquinoline is replaced by 2-bromo-4-chlorothieno[2,3-b]pyridine to obtain the title compound.
[0096] Step 2
[0097]
[0098] Intermediate 4 (0.20 g, 0.47 mmol), 2,2,2-trifluoroethylamine (precursor, 0.01 g, 0.96 mmol), palladium acetate (0.01 g, 0.04 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.05 g, 0.08 mmol), cesium carbonate (1.0 g, 1.1 mmol) were added to a three-necked flask, 1,4-dioxane (5 mL) was added to dissolve, and the mixture was stirred at 100 ° C for 4 hours under an argon atmosphere. Cool to room temperature, add water (100 mL) to dissolve, extract three times with ethyl acetate (100 mL), wash the organic phase with saturated sodium chloride aqueous solution, add anhydrous sodium sulfate to dry, and separate the crude product by column chromatography (DCM / MeOH=10 / 1) to obtain 0.06 g of white solid, with a yield of 34%. 1 H NMR (400MHz, CDCl3) δ8.44(s,1H),7.70(s,1H),7.34(s,1H),7.19(s,1H),7.01(s,1H),4.41(s,1H),4.25(d,J=12.5Hz, 1H), 4.15 (d, J = 12.3Hz, 1H), 3.68 (s, 2H), 3.57 (s, 2H), 2.99 (s, 1H), 2.16 (s, 2H), 1.15–1.10 (m, 2H), 1.06–0.98 (m, 2H). 13 C NMR (101MHz, CDCl3) δ164.08,154.88,153.84,153.04,148.39,141.70,126.9 5,126.66,120.43,114.43,114.38,68.24,55.61,48.04,35.69,33.43,13.45.
[0099] Example 6
[0100]
[0101] The preparation method is the same as that of Example 6, except that the precursor is replaced with an equimolar amount of 1-amino-2-methyl-2-propanol to obtain the title compound. 1 HNMR(500MHz, CDCl3)δ8.43(s,1H),7.85(s,1H),7.34(s,1H),7.18(s,1H),7.01(s,1H),4.41(s,1H),3.81(s,1H),3. 74–3.62(m,4H),3.57(s,2H),2.99(s,1H),2.16(s,2H),1.30(d,J=4.9Hz,2H),1.32–1.08(m,6H),0.99–0.82(m,2H). 13C NMR (101MHz, CDCl3) δ164.08,154.27,152.84,153.04,148.39,141.70,126.66,1 20.39,115.19,114.43,76.79,68.24,56.68,55.61,35.69,33.43,28.63,13.43.
[0102] Example 7
[0103]
[0104] The preparation method is the same as that of Example 6, except that the precursor is replaced with an equimolar amount of 1-methylazetidine-3-amine to obtain the title compound. 1 H NMR (400MHz, CDCl3) δ8.43(s,1H),7.33(d,J=12.6Hz,2H),7.01(s,1H),6.16(s,1H),4.41(s,1H),4.00(s,1H),3.68(s ,2H),3.57(s,2H),2.99(d,J=6.6Hz,4H),2.74(s,2H),2.30(s,3H),2.16(s,2H),1.32–1.10(m,3H),1.07–0.92(m,2H). 13 CNMR(101MHz, CDCl3)δ165.05,153.82,153.04,150.25,148.39,141.70,126.66, 120.62,114.43,113.14,68.24,60.80,55.61,55.04,44.15,35.69,33.43,13.41.
[0105] Example 8
[0106]
[0107] The preparation method is the same as that of Example 6, except that the precursor is replaced with an equimolar amount of 1-(3-aminoazetidin-1-yl)ethane-1-one to obtain the title compound. 1HNMR(400MHz, CDCl3)δ8.43(s,1H),7.33(d,J=12.6Hz,2H),7.01(s,1H),6.32(s,1H),4.41(s,1H),4.17(s,1H),3.81(s ,2H),3.68(s,2H),3.58(d,J=16.5Hz,3H),2.99(s,1H),2.16(s,2H),2.03(s,2H),1.22–1.08(m,6H),0.98–0.81(m,2H). 13 C NMR (125MHz, CDCl3) δ173.66,165.05,153.84,153.04,150.75,148.39,141.70,126. 66,120.62,114.43,113.15,68.24,56.79,55.61,51.48,35.69,33.43,22.75,13.41.
[0108] Comparative Example 1 Comparative Formula A
[0109]
[0110] The preparation method is the same as that of Example 1, except that in step 4, the precursor raw material is replaced with an equimolar amount of 1,1-dioxide-3-aminothicyclotane to prepare a comparative compound of formula A. 1 H NMR (400MHz, CDCl3) δ8.49 (d,
[0111] J=5.2Hz,1H),8.08(d,J=8.8Hz,1H),7.35(s,1H),7.18(d,J=2.0Hz,1H),6.98(dd,J=8.8,2.0Hz,1H),6.41(d,J=5.2Hz,1H),4.52(br,3H),3.93–3 .88(m,2H),3.55(tt,J=7.2,3.6Hz,1H),3.34(td,J=11.6,2.4Hz,3H),2. 83–2.75(m,1H),1.91–1.81(m,2H),1.76–1.71(m,3H),1.12–0.98(m,5H). 13 CNMR(101MHz,CDCl3)δ162.54,151.08,151.06,148.82,146.87,134.29,122.8 9,122.02,118.11,113.83,108.33,100.05,67.90,33.30,33.24,31.44,6.55.
[0112] Comparative Example 2-Comparative Formula B
[0113]
[0114] The preparation method is the same as that of Example 1, except that in step 4, the precursor material is replaced with an equimolar amount of 3-(methylsulfonyl)azetidine to prepare a comparative compound of formula B. 1 H NMR(400MHz,DMSO-d6)δ8.47(d,J
[0115] =5.2Hz,1H),8.07(d,J=9.0Hz,1H),7.91(s,1H),6.88(dd,J=9.0,2.4Hz,1H),6.7 0(d,J=2.4Hz,1H),6.41(d,J=5.2Hz,1H),4.50(s,1H),3.93(t,J=9.0Hz,2H),3.8 6(t,J=7.2Hz,2H),3.77(dt,J=11.2,3.4Hz,2H),3.71–3.63(m,1H),3.29–3.18(m ,2H),2.83–2.67(m,2H),1.69–1.60(m,4H),1.07–1.03(m,2H),0.97–0.90(m,2H). 13 C NMR(101MHz,DMSO-d6)δ161.84,152.90,152.04,151.39,145.96,134.01,123.06,122.34 ,114.79,112.33,104.85,99.90,68.30,67.30,52.58,33.69,33.04,31.71,27.08,6.62.
[0116] Comparative Example 3-Comparative Formula C
[0117]
[0118] The preparation method is the same as that of Example 1, except that in step 4, the precursor material is replaced with an equimolar amount of 4-methylsulfonyl-piperidine to prepare a comparative compound of formula C. 1 H NMR (400MHz, CDCl3) δ8.52 (d, J = 5.2Hz, 1H),
[0119] 8.13(d,J=9.2Hz,1H),7.35(s,1H),7.32(d,J=2.8Hz,1H),7.28–7.24(m,1H),6.46(d,J=5.2Hz,1H),4.03(dt,J=13.2,3 .2Hz,2H),3.90–3.82(m,2H),3.58–3.50(m,1H),3.31(td,J=11.8,2.4Hz,2H),3.07–2.98(m,1H),2.90(td,J=11.8,2.4
[0120] Hz,2H),2.83(s,3H),2.81–2.72(m,1H),2.22(d,J=10.8Hz,2H),2.02–1.76(m,4H),1.75–1.66(m,1H),1.11–1.05(m,2H),1.01–0.93(m,2H). 13 C NMR (101MHz, CDCl3) δ162.10,151.76,151.56,151.25,146.73,134.19,122.49,122.05,118 .97,114.54,111.05,100.91,67.84,60.40,48.05,37.36,33.28,33.23,31.41,24.61,6.52.
[0121] Comparative Example 4-Comparative Formula D
[0122]
[0123] The preparation method is the same as that of Example 1, except that in step 4, the precursor material is replaced with an equimolar amount of 1-cyclopropylcarbonylpiperazine to prepare a comparative formula D compound. 1 H NMR(400MHz,DMSO-d6)δ8.56(d,J=5.2Hz,
[0124] 1H),8.13(d,J=9.2Hz,1H),7.95(s,1H),7.52(dd,J=9.2,2.4Hz,1H),7.27(d,J=
[0125] 2.4Hz,1H),6.53(d,J=5.2Hz,1H),3.89(s,2H),3.78(dt,J=11.2,3.2Hz,2H),3.73–3.64(m,2H),3.43(s,2H),3.34–3.1 7(m,4H),2.81–2.69(m,1H),2.10–2.02(m,1H),1.73–1.58(m,4H),1.10–1.03(m,2H),0.99–0.92(m,2H),0.81–0.67(m,
[0126] 4H). 13 CNMR(101MHz,DMSO-d6)δ171.65,161.64,152.31,152.13,151.39,145.92,133.94,123.11 ,122.27,118.88,113.80,110.10,101.08,67.29,33.71,33.04,31.70,10.79,7.58,6.63.
[0127] Comparative Example 5:
[0128]
[0129] 1 H NMR (400MHz, DMSO-d6) δ8.59(d,J=5.2Hz,1H),8.18(d,J=9.2Hz,1H),7.96(s,1H),7.66(dd,J=9.3,2. 5Hz,1H),7.45(d,J=2.4Hz,1H),6.57(d,J=5.2Hz,1H),4.91(s,2H),4.35(t,J=5.4Hz,2H),4.04(t,J= 5.4Hz,2H),3.77(dt,J=11.3,3.4Hz,2H),3.70(tt,J=7.4,3.8Hz,1H),3.40(dd,J=8.9,5.5Hz,3H),3. 31–3.20(m,2H),2.79–2.68(m,1H),1.66(h,J=4.5,4.0Hz,4H),1.10–1.03(m,2H),0.99–0.91(m,2H).
[0130] Pharmacological tests:
[0131] Example 9 Cell proliferation assay
[0132] The effect of the compounds of the present invention on the proliferation of mouse liver cancer cells H22 was tested using in vitro cell evaluation. The detection method used in this assay is the CCK8 method, the basic principle of which is that the reagent contains a water-soluble tetrazolium salt WST-8 [chemical name: 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfonic acid benzene)-2H-tetrazolium monosodium salt], which is reduced to a highly water-soluble yellow formazan product by dehydrogenase in the cell under the action of the electron carrier 1-methoxy-5-methylphenazinium dimethyl sulfate (1-Methoxy PMS). The amount of formazan generated is proportional to the number of living cells. Therefore, this property can be used to directly perform cell proliferation and toxicity analysis.
[0133] The determination procedure is as follows:
[0134] (1) Cell plating:
[0135] H22 cells in the logarithmic growth phase were taken, digested and resuspended, and then counted, and the cell density was inoculated in a 96-well plate, with 4,000 cells per well, and the plate was placed in a 37° C., 5% CO 2 incubator for 24 hours, and then the compound of the present invention was added for treatment;
[0136] (2) Compound treatment:
[0137] The compounds of the present invention are configured for cell therapy, and the final concentrations of the compounds (in the above cases) are 1000nM, 333.3nM, 111.1nM, 37.04nM, 12.35nM, 4.115nM, 1.372nM, 0.457nM, 0.152nM, 0nM. The well plate was placed in a 37°C, 5% CO2 incubator for 72 hours. Only the medium without cells was added as a blank group; the concentration of the compound in the control group was 0nM;
[0138] (3) CCK8 detection:
[0139] After 72 hours of cell culture, 10 μL of CCK8 detection solution was added to each well, and the cells were placed in a 37°C, 5% CO2 incubator for another 2 hours. The detection value of each well was read on a multifunctional microplate reader, and the absorbance was measured at 450 nm using a microplate reader;
[0140] (4) Data analysis:
[0141] The inhibition ratio was calculated based on the OD value readings, and the inhibition percentage = (1-(drug group value-blank group value) / (control group value-blank group value))*100%. The log (inhibitor) of GraphPad Prism was used to fit the response-variable slope to quantify the curve and calculate the IC of the compound to inhibit cell proliferation. 50 value.
[0142] Table 1
[0143]
[0144]
[0145] Example 10 Cell luciferase assay evaluation
[0146] NIH3T3 mouse fibroblasts engineered to express a Smad2 / 3-luciferase responsive promoter were used. The basic principle is that after the cells are stimulated by TGF-β1 cytokine, the phosphorylation level of Smad2 / 3 downstream of the TGF-β1 receptor increases. The chemiluminescent signal intensity detected by the Bright-glo luciferase assay system is proportional to the Smad2 / 3 phosphorylation level. Therefore, this experiment can reflect the degree of inhibition of the TGF-β1 receptor.
[0147] (1) Cell plating:
[0148] NIH3T3-Smad2 / 3-Luc cells in the logarithmic growth phase were taken, digested and resuspended, and then counted. The cells were inoculated in a 96-well plate at a density of 4,000 cells per well, and the plate was placed in a 37° C., 5% CO 2 incubator for 24 hours, and then the compound of the present invention was added for treatment;
[0149] (2) Compound treatment:
[0150] The compounds of the present invention are configured for cell therapy, the final concentrations of the compounds (the above cases) are 1000nM, 333.3nM, 111.1nM, 37.04nM, 12.35nM, 4.115nM, 1.372nM, 0.457nM, 0.152nM, 0nM, and the final concentration of TGFβ1 in each well is 2.5ng / mL. The well plate is placed in a 37°C, 5% CO2 incubator for 24 hours. Only the medium without cells is added as a blank group; the concentration of the compound in the control group is 0nM;
[0151] (3) Fluorescence detection:
[0152] Remove the cell supernatant, add 100 μL Glo Lysis Buffer to each well, shake slowly, and lyse at room temperature for 5 minutes. Then add 100 μL Bright-glo luciferase assay system to each well, incubate at room temperature for 5 minutes, shake for 2 minutes, transfer 100 μL of supernatant to a 96-well plate with a white bottom, and detect the chemiluminescent signal. The detection condition is 1 second.
[0153] (4) Data analysis:
[0154] The inhibition ratio was calculated based on the OD value readings, and the inhibition percentage = (1-(drug group value-blank group value) / (control group value-blank group value))*100%. The log (inhibitor) of GraphPad Prism was used to fit the response-variable slope to quantify the curve and calculate the IC of the compound. 50 value.
[0155] Table 2
[0156]
[0157] Example 11 Test of some of the compounds in the examples on the growth inhibition of transplanted tumors in BALB / C mice
[0158] Experimental methods:
[0159] (1) H22 cells were cultured in a culture medium containing 10% fetal bovine serum, tumor cells in the logarithmic growth phase were collected, and resuspended in PBS to a suitable concentration for subcutaneous tumor inoculation in mice;
[0160] (2) The experimental mice were subcutaneously inoculated with 1×10 6 Tumor cells, regularly observe tumor growth, and wait until the tumor grows to an average volume of ~100mm 3 The mice were randomly divided into groups and given drugs according to tumor size and weight;
[0161] (3) Before drug administration, all animals were weighed and tumor volumes were measured using a vernier caliper;
[0162] (4) The example compounds were orally administered at a given dose every day for three consecutive weeks, and the solvent control group was given an equal amount of solvent. During the entire experiment, the diameter of the transplanted tumor was measured every two days, and the body weight of the mice was weighed at the same time.
[0163] The calculation formula of tumor volume (TV) is: TV = 1 / 2 × a × b 2, where a and b represent length and width, respectively. The relative tumor volume (RTV) was calculated based on the measurement results, and the calculation formula was: RTV = Vt / V0. Where V0 is the tumor volume measured when the drug was administered in cages (i.e., d0), and Vt is the tumor volume at each measurement. The evaluation indexes of antitumor activity are 1) relative tumor proliferation rate T / C (%), calculated as follows: T / C (%) = (TRTV / CRTV) × 100%, TRTV: RTV of the treatment group; CRTV: RTV of the negative control group; 2) tumor volume growth inhibition rate GI%, calculated as follows: GI% = [1-(TVt-TV0) / (CVt-CT0)] × 100%, TVt is the tumor volume measured in the treatment group each time; TV0 is the tumor volume obtained when the treatment group was administered in cages; CVt is the tumor volume measured in the control group each time; CV0 is the tumor volume obtained when the control group was administered in cages (specific data are shown in Table 3).
[0164] Table 3:
[0165]
Claims
1. A TGF-β inhibitor, It is characterized in that At least one of a compound having the structure of Formula 1 and a pharmaceutically acceptable salt, derivative, cocrystal, crystal, crystal, or solvate thereof; The Ar is a benzene ring or a five-membered aromatic heterocycle; The R is a substituted amino group, or a N-containing monocyclic ring with a substituent; wherein the N-containing monocyclic ring is a four-membered to six-membered saturated N-containing heterocyclic ring containing 1 to 2 N atoms, or a five-membered to six-membered N-containing aromatic heterocyclic ring containing 1 to 2 N atoms; the substituent includes at least one of halogen, -CN, amino, substituted amino, and alkyl.
2. The TGF-β inhibitor according to claim 1, It is characterized in that In the formula 1, the structure has formula a and / or formula b: In the above a, R is a group of the following structure: The R 1 is F or -CN; R 2 F, -CN, C 1 ~C 4 The alkyl group; Preferably, the R 1 , R 2 located on the same or different carbons; Preferably, the R 3 is an alkyl group or an amino-substituted alkyl group; Preferably, in the formula b, R is an amino group with a substituent; wherein the substituent includes an alkyl group, a cycloalkyl group, a nitrogen-containing heterocycle or a substituted alkyl group; the substituted alkyl group is an alkyl group with at least one of a hydroxyl group and a trifluoromethyl group.
3. The TGF-β inhibitor according to claim 1, It is characterized in that The formula 1 comprises at least one of the following structures; 4. A method for preparing the TGF-β inhibitor according to any one of claims 1 to 3, It is characterized in that The compound of formula 2 is coupled with a precursor material for forming an R residue; Said X is halogen.
5. The method for preparing the TGF-β inhibitor according to claim 4, It is characterized in that The precursor material is RH, which is coupled with formula 2, a base, a palladium catalyst, and a reaction aid to obtain the TGF-β inhibitor; Preferably, the auxiliary agent is 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene; Preferably, the molar ratio of RH to Formula 2, base, palladium catalyst, and reaction aid is 1.2-1.5:1:0.05-0.1:0.1-0.2; Preferably, the coupling solvent is at least one of 1,4-dioxane, N,N-dimethylformamide, and tetrahydrofuran; Preferably, the coupling reaction temperature is 90-110°C.
6. The method for preparing the TGF-β inhibitor according to claim 4, It is characterized in that The precursor material is R-(BOR 4 ) 2 , and subjecting it to Suzuki coupling with Formula 2 to obtain the TGF-β inhibitor; The R 4 It is independently H or C1-C4 alkyl.
7. Use of the TGF-β inhibitor according to any one of claims 1 to 3 in the preparation of a drug for inhibiting TGF-β expression.
8. The use according to claim 7, It is characterized in that The TGF-β mentioned above refers to TGF-β1; Preferably, it is used for preparing anti-tumor drugs.
9. An anti-tumor drug, It is characterized in that Contains a pharmaceutically effective amount of a TGF-β inhibitor.
10. An anti-tumor drug, It is characterized in that Also contains pharmaceutically acceptable excipients; Preferably, it has a pharmaceutically acceptable dosage form.
